FindTrial
Sign In

Rilimogene Galvacirepvec

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate CarcinomaStage I Prostate Adenocarcinoma AJCC v7Stage II Prostate Adenocarcinoma AJCC v7Stage IV Prostate Cancer

Phase 2

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
TerminatedNCT01145508
National Cancer Institute (NCI)Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma +1
Start: 2010-08-31End: 2015-10-31Updated: 2017-09-19
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
CompletedNCT02326805
National Cancer Institute (NCI)Stage II Prostate Adenocarcinoma AJCC v7, Stage I Prostate Adenocarcinoma AJCC v7
Start: 2015-06-03End: 2022-07-20Updated: 2023-07-19

Related Papers

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.
Journal of Clinical Oncology2022-02-162 citations